View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
October 30, 2012

TauRx Therapeutics Alzheimer’s drug enters a two-phase third trial

Pharmaceutical company TauRx Therepeutics is starting to enroll Alzheimer's patients in its third-stage clinical trial for its experimental new drug LMTX.

By Heidi Vella

TauRx Therepeutics is starting to enroll Alzheimer's patients in a Phase III study of LMTX

Pharmaceutical company TauRx Therepeutics is starting to enroll Alzheimer’s patients in its third-stage clinical trial for its experimental new drug LMTX.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Yesterday afternoon the company announced it would be going ahead with vital third-stage trials needed for regulatory approval, saying it will test LMTX on 1,300 people in 21 different countries.

It will be a two-phase clinical trial, testing people with mild Alzheimer’s and people with mild-to-moderate Alzheimer’s, with the goal of halting the progression of the disease.

The drug at the centre of the trials, LMTX, works by targeting tangles of the Tau protein in the brain, dissolving them to prevent their harmful effects to memory.

Tau tangles were first discovered in the brain in the 1990s. TauRx Therapeutics Chairman Claude Wischik has been studying the tau approach ever since as professor of old age psychiatry at the University of Aberdeen in Scotland, where the company has its main research facilities.

Wischik said; "These Phase III studies are bringing us closer to finding an effective Alzheimer’s treatment that can actually arrest the progression of the disease. It really is time to test the role of tau."

LMTX has been created from altering an earlier product called Rember. Trials from 2008 showed that Rember produced a 90% reduction rate of disease progression over two years.

Companies currently investing in TauRx Therapeutics are Temasek Holdings, Singapore’s state-owned investment company, Development Bank of Singapore and Canada’s Dundee Corp.


Image: TauRx Therapeutics third stage trials are encouraging for Alzheimer’s suffers all over the world. Photo: Courtesy of Ben Earwicker.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology